Tumefactive demyelination following treatment for relapsing multiple sclerosis with alemtuzumab

Neurology. 2017 Mar 7;88(10):1004-1006. doi: 10.1212/WNL.0000000000003694. Epub 2017 Feb 8.

¹ From the Brain & Mind Centre (J.B., T.A.H., S.W.R., M.H.B.), University of Sydney; Neuroimmunology Clinic (T.A.H., S.R., S.W.R.), Concord Repatriation General Hospital, Sydney; Sydney Neuroimaging Analysis Centre (Y.B., M.H.B.); St Vincent's Hospital (Y.B.), Sydney, Australia; and Addenbrookes Hospital (A.C.), University of Cambridge, UK.
² From the Brain & Mind Centre (J.B., T.A.H., S.W.R., M.H.B.), University of Sydney; Neuroimmunology Clinic (T.A.H., S.R., S.W.R.), Concord Repatriation General Hospital, Sydney; Sydney Neuroimaging Analysis Centre (Y.B., M.H.B.); St Vincent's Hospital (Y.B.), Sydney, Australia; and Addenbrookes Hospital (A.C.), University of Cambridge, UK. michael@sydneyneurology.com.au.

No abstract available

Publication types